[1] HAUGEN B R, AlEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
[2] GUTH S, THEUNE U, ABERLE J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination[J]. Eur J Clin Invest, 2009, 39(8):699-706.
[3] BELFIORE A, LA ROSA G L, LA PORTA G A, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity[J]. Am J Med, 1992, 93(4):363-369.
[4] YLLI D, BURMAN K D, VAN NOSTRAND D, et al. Eliminating the age cutoff in staging of differentiated thyroid cancer: the safest road[J]. J Clin Endocrinol Metab, 2018, 103(5):1813-1817.
[5] KWONG N, MEDICI M, ANGELL T E, et al. The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk[J]. J Clin Endocrinol Metab, 2015, 100(12):4434-4440.
[6] LIM H, DEVESA S S, SOSA J A, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13):1338-1348.
[7] SANTANGELO G, DEL GIUDICE S, GALLUCCI F, et al. Cancer of the thyroid gland in geriatric age: a single center retrospective study with a 10-year post-operative follow-up[J]. Int J Surg, 2014, 12(Suppl 2):S103-S107.
[8] CHEREAU N, TRÉSALLET C, NOULLET S, et al. Prognosis of papillary thyroid carcinoma in elderly patients after thyroid resection: a retrospective cohort analysis[J]. Medicine: Baltimore, 2016, 95(47):e5450.
[9] ITO Y, MIYAUCHI A, KIHARA M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 2014, 24(1):27-34.
[10] 杨卫平,邵堂雷.老年甲状腺结节的诊治经验[J].医学与哲学, 2010,31(12):17-18.
[11] 史宜鑫,陈林,陈悦.2017版TI-RADS对老年甲状腺癌的诊断价值分析[J].老年医学与保健, 2020, 26(2):299-302.[12] 忻晓洁, 张坦, 张晟.甲状腺超声影像和数据报告系统在不同性别和年龄甲状腺结节患者中的诊断价值[J].中华肿瘤杂志, 2016,38(8):602-606.
[13] WANG Z, VYAS C, VAN B, et al. Quantitative analysis of the benefits and risk of thyroid nodule evaluation in patients ≥70 years old[J].Thyroid, 2018, 28: 465-471.
[14] ELISEI R, UGOLINI C, VIOLA D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
[15] 于璐,贾海燕,袁慧娟,等.细针穿刺细胞学联合BRAFV600E基因突变检测在老年甲状腺结节患者中的诊断价值[J].中华老年医学杂志, 2019,38(1):59-62.
[16] FAGIN J A, WELLS S A Jr. Biologic and clinical perspectives on thyroid cancer[J]. N Engl J Med, 2016, 375(11):1054-1067.
[17] NIKIFOROVA M N, MERCURIO S, WALD A I, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules[J]. Cancer, 2018, 124(8):1682-1690.
[18] ALEXANDER E K, SCHORR M, KLOPPER J, et al. Multicenter clinical experience with the Afirma gene expression classifier[J]. J Clin Endocrinol Metab, 2014, 99(1):119-125.
[19] TRIMBOLI P, TREGLIA G, GIOVANELLA L. Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules:a systematic review[J].Horm Metab Res, 2015, 47(4):247-252.
[20] MEKEL M, STEPHEN A, GAZ R, et al. Thyroid surgery in octogenarians is associated with higher complication rates[J]. Surgery, 2009, 146(5):913-921.
[21] RUEL E, THOMAS S, DINAN M, et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2015, 100(4):1529-1536.
[22] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版)[J].中国肿瘤, 2018, 27(10):768-773.
[23] YUN K J, KIM W, KIM E H, et al. Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer[J]. Endocrinol Metab: Seoul, 2014, 29(3):388-393. |
